Seeking Alpha

Deutsche lowers target on Tesaro

  • "We had expected the trial to hit on nausea — we were wrong," Deutsche Bank's Robyn Karnauskas says, referencing Phase 3 results for rolapitant, Tesaro's (TSRO) NK-1 receptor antagonist.
  • Karnauskas lowers the price target on the shares to $62 from $80, noting that Deutsche now sees 40% market share for the drug.
  • "Worst case, stock could be flat near term until launch gets closer when we think many will want to own," the analyst concludes.
  • TSRO +2.2% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|